伯乐棋牌

      • <li id='0k8kr'></li>

        <dd id='0k8kr'><tbody id='0k8kr'><td id='0k8kr'><optgroup id='0k8kr'><strong id='0k8kr'></strong></optgroup><address id='0k8kr'><ul id='0k8kr'></ul></address><big id='0k8kr'></big></td><table id='0k8kr'></table></tbody><pre id='0k8kr'></pre></dd><span id='0k8kr'><b id='0k8kr'></b></span>

        • Site Search:

              <dfn id='0k8kr'><optgroup id='0k8kr'></optgroup></dfn><tfoot id='0k8kr'><bdo id='0k8kr'><div id='0k8kr'></div><i id='0k8kr'><dt id='0k8kr'></dt></i></bdo></tfoot>

              <ul id='0k8kr'></ul>

              • Content on this page requires a newer version of Adobe Flash Player.

                Technical Center Introduction
                Quality Management
                information Center
                Technological development
                Academic exchange
                Research results
                Market innovation
                Pilot correction
                Chinese name: Xiu Xiu Your graduation institution: Jilin University Xiu Xiu, full ... [Details]
                hot topics
                Simple investment
                And send a letter
                Market innovation Your current location : Home > R & D > Market Innovation

                Amend the pharmaceutical industry to continue to innovate

                Time: 2011-04-28 Source: Jilin Daily Author: reprint

                Entering the factory building of Correction Pharmaceuticals, it is difficult to imagine that its predecessor would be a dilapidated small pharmaceutical factory. The two rows of small bungalows and the crumbling doors of that year have left a deep impression on veteran workers. "At that time, the factory had not been paid for 7 months."


                In 2000, the Amendment Group invested 40 million yuan to develop the national second-class new drug "Geping", which enabled China's antihypertensive treatment drugs to keep pace with developed countries and reach the international advanced level. In 2001, the Amendment Group invested heavily in establishing a "new drug research and development center" with hundreds of products with independent intellectual property rights. It formulated and implemented near-, mid- and long-term research and development plans, and hired more than 30 well-known domestic and foreign medical experts and scientific researchers. Engaged in high-tech pharmaceutical research, to produce a generation, research and development, and reserve a generation. In the same year, Amendment Group was identified as a “National High-tech Enterprise of the Torch Program” by the Ministry of Science and Technology. Modified pharmaceutical industry guarantees the quality and efficacy of its products through technology and innovation.


                On March 18, 2002, Amendment Group won the ISO14001 environmental management system domestic and international certifications, becoming the first of many pharmaceutical companies in Jilin Province to receive this award, which means that Amendment Pharmaceuticals has a global market Green pass.


                In May 2006, the Ministry of Personnel officially approved the amendment of the Pharmaceutical Group to establish a post-doctoral research station. "This is the first post-doctoral scientific research station established by a domestic pharmaceutical company. Its establishment is of great significance to the development of the enterprise, and it marks that the amendment pharmaceutical group has entered a new stage of independent innovation." At present, the amendment group has developed a Two new drugs, four new drugs, four new drugs and three new drugs, with a total investment of nearly 100 million yuan. Among the 17 leading products, some are protected by the Chinese traditional medicine, some are specially recommended by the China Quality Association, some are awarded the Gold Prize of China's Famous Products, and some are rated as National Excellent New Products or Famous Pharmaceutical Products.

                Previous post: Repairing the pharmaceutical industry is expensive: institutional defects restrict the innovation of pharmaceutical companies
                Next: The perfect combination of thinking and strategic innovation is the key foundation and premise of product marketing
                Hot Products
                Copyright © Xiuzheng Pharmaceutical Group. All rights reserved.